VENTOLIN DISKUS POWDER

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

SALBUTAMOL (SALBUTAMOL SULFATE)

Saadav alates:

GLAXOSMITHKLINE INC

ATC kood:

R03AC02

INN (Rahvusvaheline Nimetus):

SALBUTAMOL

Annus:

200MCG

Ravimvorm:

POWDER

Koostis:

SALBUTAMOL (SALBUTAMOL SULFATE) 200MCG

Manustamisviis:

INHALATION

Ühikuid pakis:

60 DOSES

Retsepti tüüp:

Prescription

Terapeutiline ala:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0108887005; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2001-07-26

Toote omadused

_ _
_ _
_ _
_ _
_Page 1 of 24_
PRODUCT MONOGRAPH
PR
VENTOLIN DISKUS
salbutamol sulfate dry powder for inhalation
200 mcg salbutamol/blister
Bronchodilator
(beta
2
-adrenergic agonist)
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 17, 2017
Submission Control No: 207155
© 2017 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK
group of companies.
_ _
_ _
_ _
_ _
_Page 2 of 24_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................13
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
..................